Evidence map›Paper›PMID 28973019›Full record

ArticlePloS one2017

Beta-arrestin 1 regulation of reward-motivated behaviors and glutamatergic function.

Nitish Mittal, Ani Minasyan, Nicole Romaneschi, Joshua K Hakimian, Gabriel Gonzalez-Fernandez, Ralph Albert, Nina Desai, Ian A Mendez, Timothy Schallert, Sean B Ostlund and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Nitish MittalDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Ani MinasyanDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Nicole RomaneschiDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Joshua K HakimianDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Gabriel Gonzalez-FernandezDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Ralph AlbertDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Nina DesaiDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Ian A MendezDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.
Timothy SchallertDivision of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, United States of America.
Sean B OstlundDepartment of Anesthesiology and Perioperative Care, School of Medicine, University of California, Irvine, UCI Center for Addiction Neuroscience, School of Biological Sciences, University of California Irvine, Irvine, United States of America.
Wendy WalwynDepartment of Psychiatry and Biobehavioral Sciences, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States of America.ORCID http://orcid.org/0000-0003-1192-3065
University of California, Los Angeles · USThe University of Texas at Austin · USUniversity of California, Irvine · US

Funding

Cholinergic regulation of striatal neurochemistry in cue-triggered decision-makingR01MH106972 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · PI OSTLUND, SEAN BJORN · 2016 to 2020
$2.5M
Neurochemical bases for changes in decision-making across the lifespanR01AG045380 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAIDMENT, NIGEL T, MURPHY, NIALL P · 2014 to 2018
$1.9M
A novel bioengineered technique to rapidly and permanently repair cut PNS nervesR01NS081063 · NINDS · UNIVERSITY OF TEXAS AT AUSTIN · PI BITTNER, GEORGE DAVIS · 2012 to 2016
$1.7M
Cocaine-Seeking and the Transfer of Behavioral ControlR01DA029035 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OSTLUND, SEAN BJORN · 2011 to 2015
$1.5M
Cafeteria diet-induced dysregulation of food seeking: neurochemical basesR01DK098709 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAIDMENT, NIGEL T, MURPHY, NIALL P · 2014 to 2016
$1.2M
NIA NIH HHS R01 AG045380NIDA NIH HHS R01 DA029035NIDDK NIH HHS R01 DK098709NIMH NIH HHS R01 MH106972NINDS NIH HHS R01 NS081063
6 · The paper itself

Abstract

The two highly homologous non-visual arrestins, beta-arrestin 1 and 2, are ubiquitously expressed in the central nervous system, yet knowledge of their disparate roles is limited. While beta-arrestin 2 (βarr2) has been implicated in several aspects of reward-related learning and behavior, very little is known about the behavioral function of beta-arrestin 1 (βarr1). Using mice lacking βarr1, we focused on the role of this scaffolding and signal transduction protein in reward-motivated behaviors and in striatal glutamatergic function. We found that βarr1 KO mice were both slower in acquiring cocaine self-administration and in extinguishing this behavior. They also showed deficits in learning tasks supported by a natural food reward, suggesting a general alteration in reward processing. We then examined glutamatergic synaptic strength in WT and KO medium spiny neurons (MSNs) of the Nucleus Accumbens (NAc) shell in naïve animals, and from those that underwent cocaine self-administration. An increase in the AMPA/NMDA (A/N) ratio and a relative lack of GluN2B-enriched NMDARs was found in naïve KO vs WT MSNs. Applying Lim Domain Kinase (LIMK1), the kinase that phosphorylates and inactivates cofilin, to these cells, showed that both βarr1 and LIMK regulate the A/N ratio and GluN2B-NMDARs. Cocaine self-administration increased the A/N ratio and GluN2B-NMDARs in WT MSNs and, although the A/N ratio also increased in KO MSNs, this was accompanied by fewer GluN2B-NMDARs and an appearance of calcium-permeable AMPARs. Finally, to examine the consequences of reduced basal GluN2B-NMDARs in reward-processing seen in KO mice, we chronically infused ifenprodil, a GluN2B antagonist, into the NAc shell of WT mice. This intervention substantially reduced food-motivated behavior. Together these findings identify a previously unknown role of βarr1 in regulating specific reward-motivated behaviors and glutamatergic function.

Indexed as

RewardAnimalsBehavior, Animalbeta-ArrestinsCentral Nervous System StimulantsCocaineCorpus StriatumLearningMiceMice, KnockoutNeuronsNucleus AccumbensPhosphorylationReceptors, N-Methyl-D-AspartateSelf Administrationbeta-ArrestinsCentral Nervous System StimulantsCocaineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID28973019
PMCPMC5626489
OpenAlexW2760961406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.